Palo Alto, CA, United States of America

Jingyuan Ma

USPTO Granted Patents = 3 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2021-2022

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jingyuan Ma

Introduction

Jingyuan Ma is a prominent inventor based in Palo Alto, CA, known for his significant contributions to the field of pharmaceutical sciences. With a focus on calpain modulators, he has developed innovative therapeutic solutions that have the potential to impact various medical conditions. His work is characterized by a commitment to advancing healthcare through scientific research and innovation.

Latest Patents

Jingyuan Ma holds a total of 3 patents. His latest patents include compositions related to calpain modulators and their therapeutic uses. These patents disclose small molecule calpain modulator compositions and pharmaceutical compositions, detailing their use and preparation. Some embodiments of his work relate to macrocyclic α-keto amide derivatives, which are explored for their potential as therapeutic agents.

Career Highlights

Jingyuan Ma is currently associated with Blade Therapeutics, Inc., where he continues to push the boundaries of innovation in drug development. His expertise in calpain modulation has positioned him as a key figure in the pharmaceutical industry, contributing to the advancement of new therapeutic strategies.

Collaborations

Jingyuan has collaborated with notable colleagues, including Brad Owen Buckman and John Beamond Nicholas. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Jingyuan Ma's work exemplifies the spirit of innovation in the pharmaceutical field. His contributions through patents and collaborations highlight his dedication to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…